{"id":"flox","rwe":[{"pmid":"41912060","year":"2026","title":"Piezo1 mediates mechanical strain-induced bone remodeling in TMJ condylar cartilage via PI3K/Akt signaling.","finding":"","journal":"Bone","studyType":"Clinical Study"},{"pmid":"41904577","year":"2026","title":"Endothelial tPA-dependent recruitment of microglia to vessels protects the blood-brain barrier after stroke.","finding":"","journal":"Fluids and barriers of the CNS","studyType":"Clinical Study"},{"pmid":"41898549","year":"2026","title":"Renal Tubule-Specific Deletion of Nephrocystin 3 (Nphp3) Causes Infantile Nephronophthisis-like Phenotypes in Mice.","finding":"","journal":"International journal of molecular sciences","studyType":"Clinical Study"},{"pmid":"41895684","year":"2026","title":"Colon-restricted Pten haploinsufficiency models PI3K pathway-driven invasion in colorectal cancer.","finding":"","journal":"Cellular and molecular gastroenterology and hepatology","studyType":"Clinical Study"},{"pmid":"41894254","year":"2026","title":"Forkhead box protein M1 network induction and crosstalk drives the development of alcohol-associated liver disease.","finding":"","journal":"Hepatology (Baltimore, Md.)","studyType":"Clinical Study"}],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"Off-Patent","category":"patent"},{"label":"Generic Available","category":"availability"},{"label":"Active","category":"status"},{"label":"Hospira","category":"company"}],"phase":"marketed","safety":{"commonSideEffects":[{"effect":"Nausea","drugRate":"","severity":"common","organSystem":""},{"effect":"Vomiting","drugRate":"","severity":"common","organSystem":""},{"effect":"Diarrhea","drugRate":"","severity":"common","organSystem":""},{"effect":"Enteritis","drugRate":"","severity":"common","organSystem":""},{"effect":"Stomatitis","drugRate":"","severity":"common","organSystem":""},{"effect":"Localized erythema","drugRate":"","severity":"common","organSystem":""},{"effect":"Anemia","drugRate":"","severity":"common","organSystem":""},{"effect":"Leukopenia","drugRate":"","severity":"common","organSystem":""},{"effect":"Thrombocytopenia","drugRate":"","severity":"common","organSystem":""},{"effect":"Elevated alkaline phosphatase","drugRate":"","severity":"common","organSystem":""},{"effect":"Elevated serum transaminase","drugRate":"","severity":"common","organSystem":""},{"effect":"Elevated serum bilirubin","drugRate":"","severity":"common","organSystem":""},{"effect":"Elevated lactic dehydrogenase","drugRate":"","severity":"common","organSystem":""},{"effect":"Anorexia","drugRate":"","severity":"common","organSystem":""},{"effect":"Abdominal pain","drugRate":"","severity":"common","organSystem":""},{"effect":"Cramps","drugRate":"","severity":"common","organSystem":""},{"effect":"Fever","drugRate":"","severity":"common","organSystem":""},{"effect":"Lethargy","drugRate":"","severity":"common","organSystem":""},{"effect":"Malaise","drugRate":"","severity":"common","organSystem":""},{"effect":"Weakness","drugRate":"","severity":"common","organSystem":""}],"contraindications":["Acute hemorrhage","Acute infectious disease","Anemia","Bone marrow depression","Breastfeeding (mother)","Cholecystitis","Disease of liver","Esophagitis","Fibrosis of bile duct","Gastrointestinal hemorrhage","Gastrointestinal ulcer","Hyperbilirubinemia","Kidney disease","Leukopenia","Liver function tests abnormal","Myocardial ischemia","Nutritional disorder","Persistent vomiting","Pharyngitis","Pregnancy, function","Stomatitis","Thrombocytopenic disorder"],"seriousAdverseEvents":[{"effect":"Arterial thrombosis","drugRate":"","severity":"serious"},{"effect":"Arterial aneurysm","drugRate":"","severity":"serious"},{"effect":"Arterial ischemia","drugRate":"","severity":"serious"},{"effect":"Hepatic necrosis","drugRate":"","severity":"serious"},{"effect":"Myocardial ischemia","drugRate":"","severity":"serious"},{"effect":"Embolism","drugRate":"","severity":"serious"},{"effect":"Thrombophlebitis","drugRate":"","severity":"serious"},{"effect":"Duodenal ulcer","drugRate":"","severity":"serious"},{"effect":"Acalculous cholecystitis","drugRate":"","severity":"serious"},{"effect":"Anaphylaxis","drugRate":"","severity":"serious"}]},"trials":[],"aliases":["Oxaliplatin","5-fluorouracil","Leucovorin"],"company":"Hospira","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=FLOX","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T01:05:28.159158+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T01:05:41.177351+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T01:05:33.987417+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=FLOX","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T01:05:34.449290+00:00"}},"allNames":["flox"],"offLabel":[],"synonyms":[],"timeline":[{"date":"2000-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from University Hospital, Akershus to Hospira"},{"date":"2000-04-16","type":"neutral","source":"FDA Orange Book","milestone":"Generic entry — 1 manufacturer approved"}],"aiSummary":"Flox, marketed by Hospira, is a therapeutic agent indicated for malignant neoplasm of the liver. The drug's key composition patent is set to expire in 2028, providing a period of market exclusivity. The primary risk lies in the lack of reported key trial results and revenue data, which may affect investor confidence and market positioning.","approvals":[],"ecosystem":[],"mechanism":{"target":"Thymidylate synthase, Thymidylate synthase","modality":"Small Molecule","explanation":"","oneSentence":"","technicalDetail":"Flox is a small molecule that binds to a specific protein or receptor, altering its activity and leading to a therapeutic effect."},"commercial":{},"references":[{"id":1,"url":"https://clinicaltrials.gov/search?intr=flox","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=flox","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-31T10:16:38.102237","_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T01:05:41.177429+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[],"genericName":"flox","indications":{"approved":[{"name":"Malignant neoplasm of liver","diseaseId":"malignant-neoplasm-of-liver","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Primary malignant neoplasm of gastrointestinal tract","diseaseId":"primary-malignant-neoplasm-of-gastrointestinal-tract","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"currentOwner":"Hospira","drugCategory":"active","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[],"trialDetails":[{"nctId":"NCT03388190","phase":"PHASE2","title":"METIMMOX: Colorectal Cancer METastasis - Shaping Anti-tumor IMMunity by OXaliplatin","status":"COMPLETED","sponsor":"University Hospital, Akershus","startDate":"2018-05-29","conditions":["Colorectal Cancer Metastatic"],"enrollment":80,"completionDate":"2024-03-18"},{"nctId":"NCT05504252","phase":"PHASE2","title":"METIMMOX-2: Metastatic pMMR/MSS Colorectal Cancer - Shaping Anti-Tumor Immunity by Oxaliplatin","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Hospital, Akershus","startDate":"2022-10-05","conditions":["Colorectal Adenocarcinoma","Mucinous Adenocarcinoma","Signet Ring Cell Adenocarcinoma"],"enrollment":80,"completionDate":"2028-03-01"},{"nctId":"NCT03724994","phase":"","title":"Chemotherapy, Host Response and Molecular Dynamics in Periampullary Cancer","status":"COMPLETED","sponsor":"Lund University","startDate":"2018-10-30","conditions":["Periampullary Adenocarcinoma","Periampullary Cancer","Pancreatic Cancer"],"enrollment":201,"completionDate":"2024-12-31"},{"nctId":"NCT04423731","phase":"","title":"Neoadjuvant Chemotherapy in Borderline Resectable and Locally Advanced Pancreatic Cancer (NORPACT-2)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Oslo University Hospital","startDate":"2018-01-01","conditions":["Locally Advanced Pancreatic Adenocarcinoma","Chemotherapy Effect","Borderline Resectable Pancreatic Adenocarcinoma","Pancreatectomy"],"enrollment":251,"completionDate":"2025-12-31"},{"nctId":"NCT03542136","phase":"NA","title":"Peripheral Neuropathy in Colorectal Cancer Patients Under Adjuvant Chemotherapy With FOLFOX, FLOX or XELOX Regime","status":"COMPLETED","sponsor":"Lund University Hospital","startDate":"2018-06-04","conditions":["Colorectal Cancer"],"enrollment":30,"completionDate":"2020-11-30"},{"nctId":"NCT02244632","phase":"PHASE1,PHASE2","title":"Modufolin (Arfolitixorin) in Combination With 5-Fluorouracil Alone or Together With Oxaliplatin or Irinotecan in Colorectal Cancer","status":"COMPLETED","sponsor":"Isofol Medical AB","startDate":"2014-09","conditions":["Colorectal Neoplasm"],"enrollment":105,"completionDate":"2020-01-30"},{"nctId":"NCT01450163","phase":"PHASE3","title":"Evaluate The Efficacy and Safety Of Pregabalin In Prevention, Reduction of Oxaliplatin-Induced Painful Neuropathy","status":"COMPLETED","sponsor":"University of Sao Paulo","startDate":"2011-08","conditions":["Pain","Neuropathic Pain","Polyneuropathy"],"enrollment":200,"completionDate":"2014-12"},{"nctId":"NCT00660582","phase":"PHASE2","title":"FLOX + Cetuximab (Erbitux®) for Patients With Metastatic Colorectal Cancer and Wild Type K-RAS Tumor","status":"COMPLETED","sponsor":"Per Pfeiffer","startDate":"2008-04","conditions":["Metastatic Colorectal Cancer"],"enrollment":152,"completionDate":"2013-02"},{"nctId":"NCT01941979","phase":"PHASE3","title":"A Study Comparing Adjuvant Chemotherapy Versus Observation for Patients With Rectal Adenocarcinoma After Neoadjuvant Chemo-Radiotherapy Treatment.","status":"UNKNOWN","sponsor":"Instituto do Cancer do Estado de São Paulo","startDate":"2011-09","conditions":["Rectal Cancer"],"enrollment":309,"completionDate":"2016-09"},{"nctId":"NCT01379482","phase":"PHASE2","title":"Neo-adjuvant Chemo + Peritonectomy + Hyperthermic Intraperitoneal Chemo in Peritoneal Carcinomatosis From Gastric Cancer","status":"COMPLETED","sponsor":"Uppsala University","startDate":"2005-01","conditions":["Peritoneal Carcinomatosis","Gastric Cancer"],"enrollment":18,"completionDate":"2009-03"},{"nctId":"NCT00145314","phase":"PHASE3","title":"FLOX in Combination With Cetuximab in First-line Treatment of Colorectal Cancer","status":"COMPLETED","sponsor":"The Nordic Colorectal Cancer Biomodulation Group","startDate":"2005-05","conditions":["Metastatic Colorectal Cancer"],"enrollment":571,"completionDate":"2010-08"},{"nctId":"NCT00447967","phase":"PHASE2","title":"Combination of CPT-11 and LoHP vs Combination of 5-FU, Leucovorin and LoHP as 1st Line Treatment in Gastric Patients","status":"COMPLETED","sponsor":"Hellenic Oncology Research Group","startDate":"2004-07","conditions":["Gastric Cancer"],"enrollment":110,"completionDate":"2008-09"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"_patentsChecked":true,"formularyStatus":[],"_enricherVersion":"v2-openfda","developmentCodes":[],"ownershipHistory":[{"period":"","companyName":"University Hospital, Akershus","relationship":"Original Developer"},{"period":"present","companyName":"Hospira","relationship":"Current Owner"}],"publicationCount":2592,"therapeuticAreas":["Oncology"],"biosimilarFilings":[],"originalDeveloper":"University Hospital, Akershus","recentPublications":[{"date":"2026 Mar 28","pmid":"41912060","title":"Piezo1 mediates mechanical strain-induced bone remodeling in TMJ condylar cartilage via PI3K/Akt signaling.","journal":"Bone"},{"date":"2026 Mar 28","pmid":"41904577","title":"Endothelial tPA-dependent recruitment of microglia to vessels protects the blood-brain barrier after stroke.","journal":"Fluids and barriers of the CNS"},{"date":"2026 Mar 15","pmid":"41898549","title":"Renal Tubule-Specific Deletion of Nephrocystin 3 (Nphp3) Causes Infantile Nephronophthisis-like Phenotypes in Mice.","journal":"International journal of molecular sciences"},{"date":"2026 Mar 25","pmid":"41895684","title":"Colon-restricted Pten haploinsufficiency models PI3K pathway-driven invasion in colorectal cancer.","journal":"Cellular and molecular gastroenterology and hepatology"},{"date":"2026 Mar 27","pmid":"41894254","title":"Forkhead box protein M1 network induction and crosstalk drives the development of alcohol-associated liver disease.","journal":"Hepatology (Baltimore, Md.)"}],"companionDiagnostics":[],"genericManufacturers":3,"_genericFilersChecked":true,"genericManufacturerList":["Am Regent","Fresenius Kabi Usa","Hikma"],"status":"active","brandName":"FLOX","companyName":"Hospira","companyId":"hospira","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":50,"withResults":8},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T01:05:41.177429+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}